At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
PD-0332991drug
Likely dose
PD-0332991 125mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of PD-0332991 in Adult Patients With Advanced Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·interventional·Posted May 19, 2011·Updated Jul 28, 2025
In Brief
A Phase 2 clinical trial evaluating PD-0332991 for Advanced Hepatocellular Carcinoma and 2 related conditions. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This is a Phase 2 Study of PD-0332991 in the treatment of patients with Advanced Hepatocellular Carcinoma (HCC), a type of adenocarcinoma and the most common type of liver tumor. PD-0332991 is a compound that stops the tumor cell from entering the Synthesis phase of the cell cycle, therefore stopping DNA multiplication and decreased tumor cell copying.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Hepatocellular Carcinoma, HCC, Liver Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartMay 2011
Primary CompletionJun 2023
Study CompletionDec 2023
TodayJul 2026
First PostedMay 19, 2011
Enrollment StartMay 25, 2011
Primary CompletionJun 1, 2023
Study CompletionDec 16, 2023
TodayJul 2, 2026
Enrollment to primary: 12.0 yearsPosted 15.1 years ago
Interventions
PD-0332991drug
PD-0332991, 125mg, 3 cycles